Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces a poster presentation at the Society for Immunotherapy of Cancer (SITC). The poster, entitled Natural killer (NK) cells orchestrate the antitumor activities of Listeria monocytogenes (Lm)-based immunotherapy, evaluated the impact of Lm-based immunotherapy on the activation of NK cells in a murine model of human papillomavirus (HPV)-associated tumors.
Poster Number P520 will be presented by Sandy Hayes, Ph.D., Sr. Director, Research – BioMarkers and Immune Monitoring, on Saturday, November 10, 2018 from 12:20 “ 1:50 p.m. and 7:00 “ 8:30 p.m. Eastern time at the 2018 SITC 33rd annual meeting at the Walter E. Washington Convention Center in Washington, D.C.
The results demonstrate that AXAL can induce changes in the tumor microenvironment that promote NK cell activation, establish cross-talk between dendritic cells (DC cells), NK cells, and can facilitate trafficking of tumor antigen-specific T cells into the tumor core which we believe contribute to the antitumor activity of AXAL, said Robert G. Petit, Ph.D., Executive Vice President and Chief Scientific Officer of Advaxis. The critical role of NK cells and NK-DC crosstalk is part of the broad-based immunologic profile associated with Advaxis Lm vectors and their favorable alteration of the microenvironment for immunotherapy of solid tumors.
About Axalimogene Filolisbac
Axalimogene filolisbac is a targeted Listeria monocytogenes (Lm)-based immunotherapy that attacks HPV-associated cancers by altering a live strain of Lm bacteria to generate cancer-fighting T cells against cancer antigens while neutralizing the tumors natural protections that guard the tumor microenvironment from immunologic attack that is currently in Phase 3 clinical testing. In a Phase 2 trial evaluating axalimogene filolisbac for the treatment of persistent or recurrent metastatic (squamous or non-squamous cell) carcinoma of the cervix (PRmCC), the drug candidate showed a 12-month overall survival rate of 38% in 50 patients. This is a 52% improvement over the 12-month overall survival rate that was expected in the trials patient population based on prognostic factors.
WANT TO BUILD A FINANCIAL EMPIRE?
Subscribe to the Global Banking & Finance Review Newsletter for FREE Get Access to Exclusive Reports to Save Time & Money
By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
Axalimogene filolisbac has received Fast Track designation for adjuvant therapy for high-risk locally advanced cervical cancer (HRLACC) and a Special Protocol Assessment for the Phase 3 AIM2CERV trial in HRLACC patients. The immunotherapy has also received orphan drug designation in three clinical indications.
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on the discovery, development and commercialization of proprietary Lm-based antigen delivery products. These immunotherapies are based on a platform technology that utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. These Lm-based strains are believed to be a significant advancement in immunotherapy as they integrate multiple functions into a single immunotherapy and are designed to access and direct antigen presenting cells to stimulate anti-tumor T cell immunity, activate the immune system with the equivalent of multiple adjuvants, and simultaneously reduce tumor protection in the tumor microenvironment to enable the T cells to eliminate tumors. Advaxis has four franchises in various stages of clinical and preclinical development: HPV-associated cancers, neoantigen therapy, hotspot cancer antigens and prostate cancer.
To learn more about Advaxis, visit www.advaxis.com and connect on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements, including, but not limited to, statements regarding Advaxis ability to develop and commercialize the next generation of cancer immunotherapies, and the safety and efficacy of Advaxis proprietary immunotherapies. These forward-looking statements are subject to a number of risks including the risk factors set forth from time to time in Advaxis SEC filings including, but not limited to, its report on Form 10-K for the fiscal year ended October 31, 2017, and on Form 10-Q for the quarter ended September 30, 2018, which are available at www.sec.gov.
Any forward-looking statements set forth in this presentation speak only as of the date of this presentation. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof other than as required by law. You are cautioned not to place undue reliance on any forward-looking statements.